The 1 analysts offering 12-month price forecasts for Statera Biopharma Inc have a median target of 40.00, with a high estimate of 40.00 and a low estimate of 40.00. The median estimate represents a +1,112.12% increase from the last price of 3.30.
The current consensus among 1 polled investment analysts is to Hold stock in Statera Biopharma Inc. This rating has held steady since March, when it was unchanged from a Hold rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share --
Reporting Date TBD
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.